UBS analyst Trung Huynh lowered the firm’s price target on Cabaletta Bio (CABA) to $7 from $10 and keeps a Buy rating on the shares. A new Gr3 ICANS case has been flagged, but appears to be related to protocol deviation, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CABA:
- Cabaletta Bio price target lowered to $22 from $30 at Morgan Stanley
- Cabaletta Bio: Strong Clinical Progress and Financial Stability Drive Buy Rating
- Cabaletta Bio price target lowered to $3 from $6 at Wells Fargo
- Cabaletta Bio price target lowered to $13 from $26 at Stifel
- Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue